Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China; Department of General Surgery, Affiliated Zhongshan Hospital of Dalian University, Dalian, 116001, PR China.
Department of General Surgery, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, PR China.
Biomed Pharmacother. 2018 Oct;106:134-141. doi: 10.1016/j.biopha.2018.05.116. Epub 2018 Jun 26.
Long non-coding RNAs (lncRNAs) have emerged as key regulators in the development of hepatocellular carcinoma (HCC). In the present study, we explored the expression profile and biological role of lncRNA FEZF1-AS1 in HCC. We observed remarkable upregulation of FEZF1-AS1 in HCC tissues and cell lines, and high FEZF1-AS1 expression was correlated with aggressive phenotypes and poor prognosis of HCC patients. Furthermore, we found that FEZF1-AS1 knockdown markedly inhibited the proliferation of HCC cells by inducing cell cycle arrest. In addition, FEZF1-AS1 knockdown suppressed HCC tumor growth in vivo. Moreover, FEZF1-AS1 knockdown inhibited the migration and invasion of HCC cells through suppression of JAK2/STAT3 signaling-mediated epithelial-mesenchymal transition (EMT). In conclusion, the present study for the first time demonstrated that FEZF1-AS1 serves as an oncogenic lncRNA in human HCC and implicated FEZF1-AS1 as a valuable therapeutic target for HCC treatment.
长链非编码 RNA(lncRNA)已成为肝细胞癌(HCC)发生发展的关键调控因子。本研究旨在探讨 lncRNA FEZF1-AS1 在 HCC 中的表达谱和生物学作用。我们观察到 FEZF1-AS1 在 HCC 组织和细胞系中显著上调,且高 FEZF1-AS1 表达与 HCC 患者侵袭性表型和不良预后相关。此外,我们发现 FEZF1-AS1 敲低通过诱导细胞周期停滞显著抑制 HCC 细胞的增殖。此外,FEZF1-AS1 敲低通过抑制 JAK2/STAT3 信号转导介导的上皮-间充质转化(EMT)抑制 HCC 肿瘤在体内的生长。总之,本研究首次证明 FEZF1-AS1 作为人类 HCC 的致癌 lncRNA 发挥作用,并暗示 FEZF1-AS1 可作为 HCC 治疗的有价值的治疗靶点。